Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA

Savient Pharmaceuticals

announced that data providing further clarity and context surrounding the risk for and management of infusion reactions that may occur with KRYSTEXXA in the treatment of refractory chronic gout patients will be presented at the American College of Rheumatology Annual Scientific Meeting in Chicago. Additionally, the results from several Savient-sponsored studies highlighting the health-related quality of life and economic impact of inadequately-controlled gout and RCG will also be presented at the meeting. A post-hoc analysis of data from the pivotal Phase III KRYSTEXXA clinical trials and an open-label extension study further characterized the signs and symptoms of infusion reactions and anaphylaxis and their management in the context of the clinical studies. While all patients studied were pre-medicated to decrease the potential risk of these events, the data also confirmed that risk of infusion reactions and anaphylaxis could be mitigated by the monitoring of serum uric acid prior to each infusion and discontinuing of KRYSTEXXA treatment when SUA rises to above 6 mg/dL. "These data contribute to the growing body of evidence supporting the profile and clinical utility of KRYSTEXXA," said John H. Johnson, Chief Executive Officer and President of Savient Pharmaceuticals. "Savient remains focused on educating healthcare professionals about KRYSTEXXA and its role in helping patients who have not found success with available conventional therapies to gain control of their RCG."